Digestive Diseases and Sciences

, Volume 57, Issue 1, pp 133–141 | Cite as

Outcome Predictors for Thiopurine Maintenance Therapy in Patients with Crohn’s Disease

  • Jae Jun Park
  • Jae Hee Cheon
  • Sung Pil Hong
  • Tae Il Kim
  • Won Ho Kim
Original Article



Little is known about the factors that predict clinical relapse in Crohn’s disease patients receiving thiopurine therapy to maintain remission. The objective of this study was, therefore, to investigate these factors.


A total of 82 Crohn’s disease patients who received their first course of azathioprine or 6-mercaptopurine treatment at Severance Hospital between June 1996 and July 2007 were recruited to the study. During the follow-up period (25.5 ± 16.6 months) 19 patients (23.2%) discontinued the medication because of significant adverse effects. Forty-five patients who continued to receive thiopurines to maintain medically or surgically induced remission were enrolled in the study. After adjusting the maintenance dose, patients in remission were followed at 2–3 month intervals. Relapse was defined as a Crohn’s disease activity index ≥150.


The male-to-female ratio was 1.5:1 and the mean age was 26.3 ± 7.1 years. Cumulative relapse was 18.0% after one year and 49.2% after three years. According to multivariate Cox regression analysis, younger age (<30 years) at thiopurine therapy and increased C-reactive protein level (≥0.5 mg/dL) at remission were independent predictors of relapse (hazard ratio 19.751, 95%-confidence interval (CI) 1.996–195.402, P = 0.011 and hazard ratio 9.001, 95% CI 1.583–51.181, P = 0.013, respectively).


Younger age (<30 years) and increased C-reactive protein level at remission were independent predictors of relapse in Crohn’s disease patients receiving thiopurines to maintain remission. These high-risk groups warrant closer observation and possibly early introduction of biological agents.


Thiopurine Crohn’s disease Relapse Predictor 


  1. 1.
    Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn’s disease patients. Scand J Gastroenterol. 1995;30:699–706.PubMedCrossRefGoogle Scholar
  2. 2.
    Loftus EV Jr, Sandborn WJ. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am. 2002;31:1–20.PubMedCrossRefGoogle Scholar
  3. 3.
    Munkholm P, Langholz E, Nielsen OH, et al. Incidence and prevalence of Crohn’s disease in the county of Copenhagen, 1962–1987: a sixfold increase in incidence. Scand J Gastroenterol. 1992;27:609–614.PubMedCrossRefGoogle Scholar
  4. 4.
    Yang SK, Yun S, Kim JH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986–2005: a KASID study. Inflamm Bowel Dis. 2008;14:542–549.PubMedCrossRefGoogle Scholar
  5. 5.
    Kim ES, Kim WH. Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics. Gut Liver. 2010;4:1–14.PubMedCrossRefGoogle Scholar
  6. 6.
    Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis. 2002;8:244–250.PubMedCrossRefGoogle Scholar
  7. 7.
    Pearson DC, May GR, Fick G, et al. Azathioprine for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev. 2000;2:CD000067.Google Scholar
  8. 8.
    Peyrin-Biroulet L, Deltenre P, Ardizzone S, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn’s disease: a meta-analysis. Am J Gastroenterol. 2009;104:2089–2096.PubMedCrossRefGoogle Scholar
  9. 9.
    Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut. 1995;37:674–678.PubMedCrossRefGoogle Scholar
  10. 10.
    Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2–6; discussion 16–19.Google Scholar
  11. 11.
    Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology. 2002;122:512–530.PubMedCrossRefGoogle Scholar
  12. 12.
    Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002;50:485–489.PubMedCrossRefGoogle Scholar
  13. 13.
    Kim PS, Zlatanic J, Korelitz BI, et al. Optimum duration of treatment with 6-mercaptopurine for Crohn’s disease. Am J Gastroenterol. 1999;94:3254–3257.PubMedCrossRefGoogle Scholar
  14. 14.
    Murakami Y, Matsui T, Hirai F, et al. Efficacy of azathioprine in mild or moderate relapse in Crohn’s disease: clinical and endoscopic evaluation. Dig Endosc. 2010;22:25–32.PubMedCrossRefGoogle Scholar
  15. 15.
    Thia KT, Loftus EV Jr, Sandborn WJ, et al. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol. 2008;103:3167–3182.PubMedCrossRefGoogle Scholar
  16. 16.
    Sahmoud T, Hoctin-Boes G, Modigliani R, et al. Identifying patients with a high risk of relapse in quiescent Crohn’s disease. The GETAID group. The groupe d’Etudes Therapeutiques des affections inflammatoires digestives. Gut. 1995;37:811–818.PubMedCrossRefGoogle Scholar
  17. 17.
    Consigny Y, Modigliani R, Colombel JF, et al. A simple biological score for predicting low risk of short-term relapse in Crohn’s disease. Inflamm Bowel Dis. 2006;12:551–557.PubMedCrossRefGoogle Scholar
  18. 18.
    Cosnes J, Carbonnel F, Beaugerie L, et al. Effects of cigarette smoking on the long-term course of Crohn’s disease. Gastroenterology. 1996;110:424–431.PubMedCrossRefGoogle Scholar
  19. 19.
    Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3:521–533.PubMedCrossRefGoogle Scholar
  20. 20.
    Macdonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science. 2005;307:1920–1925.PubMedCrossRefGoogle Scholar
  21. 21.
    Ginaldi L, De Martinis M, D’Ostilio A, et al. The immune system in the elderly: II. Specific cellular immunity. Immunol Res. 1999;20:109–115.PubMedCrossRefGoogle Scholar
  22. 22.
    D’Inca R, Bertomoro P, Mazzocco K, et al. Risk factors for non-adherence to medication in inflammatory bowel disease patients. Aliment Pharmacol Ther. 2008;27:166–172.PubMedCrossRefGoogle Scholar
  23. 23.
    Horne R, Parham R, Driscoll R, et al. Patients’ attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:837–844.PubMedCrossRefGoogle Scholar
  24. 24.
    Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:661–665.PubMedCrossRefGoogle Scholar
  25. 25.
    Desai D, Faubion WA, Sandborn WJ. Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther. 2007;25:247–255.PubMedCrossRefGoogle Scholar
  26. 26.
    Boirivant M, Leoni M, Tariciotti D, et al. The clinical significance of serum C reactive protein levels in Crohn’s disease. Results of a prospective longitudinal study. J Clin Gastroenterol. 1988;10:401–405.PubMedCrossRefGoogle Scholar
  27. 27.
    Papi C, Festa V, Leandro G, et al. Long-term outcome of Crohn’s disease following corticosteroid-induced remission. Am J Gastroenterol. 2007;102:814–819.PubMedCrossRefGoogle Scholar
  28. 28.
    Solem CA, Loftus EV Jr, Tremaine WJ, et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:707–712.PubMedCrossRefGoogle Scholar
  29. 29.
    Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. Inflamm Bowel Dis. 2009;15:1295–1301.PubMedCrossRefGoogle Scholar
  30. 30.
    Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology. 2010;138:463–468; quiz e410–e461.Google Scholar
  31. 31.
    Devlin SM, Panaccione R. Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. Gastroenterol Clin North Am. 2009;38:577–594.PubMedCrossRefGoogle Scholar
  32. 32.
    Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–1395.PubMedCrossRefGoogle Scholar
  33. 33.
    Lautenbach E, Berlin JA, Lichtenstein GR. Risk factors for early postoperative recurrence of Crohn’s disease. Gastroenterology. 1998;115:259–267.PubMedCrossRefGoogle Scholar
  34. 34.
    Bitton A, Dobkin PL, Edwardes MD, et al. Predicting relapse in Crohn’s disease: a biopsychosocial model. Gut. 2008;57:1386–1392.PubMedCrossRefGoogle Scholar
  35. 35.
    Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2010;6:CD000545.Google Scholar
  36. 36.
    Kim JH, Cheon JH, Hong SS, et al. Influences of thiopurine methyltransferase genotype and activity on thiopurine-induced leukopenia in Korean patients with inflammatory bowel disease: a retrospective cohort study. J Clin Gastroenterol. 2010;44:242–248.CrossRefGoogle Scholar
  37. 37.
    Hindorf U, Lindqvist M, Peterson C, et al. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut. 2006;55:1423–1431.PubMedCrossRefGoogle Scholar
  38. 38.
    Gisbert JP, Nino P, Rodrigo L, et al. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. Am J Gastroenterol. 2006;101:2769–2776.PubMedCrossRefGoogle Scholar
  39. 39.
    Zelinkova Z, Derijks LJ, Stokkers PC, et al. Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin Gastroenterol Hepatol. 2006;4:44–49.PubMedCrossRefGoogle Scholar
  40. 40.
    Lowry PW, Franklin CL, Weaver AL, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut. 2001;49:656–664.PubMedCrossRefGoogle Scholar
  41. 41.
    Gilissen LP, Bierau J, Derijks LJ, et al. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. Aliment Pharmacol Ther. 2005;22:605–611.PubMedCrossRefGoogle Scholar
  42. 42.
    Hande S, Wilson-Rich N, Bousvaros A, et al. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm Bowel Dis. 2006;12:251–257.PubMedCrossRefGoogle Scholar
  43. 43.
    Shah JA, Edwards CM, Probert CS. Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: an audit of adverse events and outcome. Eur J Gastroenterol Hepatol. 2008;20:169–173.PubMedCrossRefGoogle Scholar
  44. 44.
    Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol. 1995;39:456–459.PubMedGoogle Scholar
  45. 45.
    Kim JH, Cheon JH, Kim WH. The frequency and the course of the adverse effects of azathioprine/6-mercaptopurine treatment in patients with inflammatory bowel disease. Korean J Gastroenterol. 2008;51:291–297.PubMedGoogle Scholar
  46. 46.
    Lee HJ, Yang SK, Kim KJ, et al. The safety and efficacy of azathioprine and 6-mercaptopurine in the treatment of Korean patients with Crohn’s disease. Intest Res. 2009;7:22–31.Google Scholar
  47. 47.
    Cheon JH, Kim JH, Kim BY, et al. Allele frequency of thiopurine methyltransferase and inosine triphosphate pyrophosphatase gene polymorphisms in Korean patients with inflammatory bowel diseases. Hepatogastroenterology. 2009;56:421–423.PubMedGoogle Scholar
  48. 48.
    Jung YS, Cheon JH, Park JJ, et al. Correlation of genotypes for thiopurine methyltransferase and inosine triphosphate pyrophosphatase with long-term clinical outcomes in Korean patients with inflammatory bowel diseases during treatment with thiopurine drugs. J Hum Genet. 2010;55:121–123.PubMedCrossRefGoogle Scholar
  49. 49.
    Kim DU, Kim YH, Kim BJ, et al. The efficacy of low dose azathioprine/6-mercaptopurine in patients with inflammatory bowel disease. Hepatogastroenterology. 2009;56:1395–1402.PubMedGoogle Scholar
  50. 50.
    Hibi T, Naganuma M, Kitahora T, et al. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol. 2003;38:740–746.PubMedCrossRefGoogle Scholar
  51. 51.
    Andoh A, Tsujikawa T, Ban H, et al. Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol. 2008;23:1373–1377.PubMedCrossRefGoogle Scholar
  52. 52.
    Thia KT, Li M, Ling KL, et al. Azathioprine is effective in corticosteroid-dependent Asian inflammatory bowel disease patients. Inflamm Bowel Dis. 2011;17:809–815.PubMedCrossRefGoogle Scholar
  53. 53.
    Korelitz BI, Present DH. Favorable effect of 6-mercaptopurine on fistulae of Crohn’s disease. Dig Dis Sci. 1985;30:58–64.PubMedCrossRefGoogle Scholar
  54. 54.
    Ha C, Dassopoulos T. Thiopurine therapy in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2010;4:575–588.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Jae Jun Park
    • 1
    • 2
    • 4
  • Jae Hee Cheon
    • 1
    • 2
    • 3
  • Sung Pil Hong
    • 1
    • 2
  • Tae Il Kim
    • 1
    • 2
  • Won Ho Kim
    • 1
    • 2
    • 3
  1. 1.Department of Internal MedicineYonsei University College of MedicineSeoulKorea
  2. 2.Institute of GastroenterologyYonsei University College of MedicineSeoulKorea
  3. 3.Brain Korea 21 Project for Medical ScienceYonsei University College of MedicineSeoulKorea
  4. 4.Department of Internal MedicineKyung Hee University Hospital at Gangdong, Kyung Hee UniversitySeoulKorea

Personalised recommendations